NCT04191499 2026-03-17INAVO120Hoffmann-La RochePhase 2/3 Active not recruiting325 enrolled 14 charts 1 FDA
NCT05104866 2026-02-04A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)AstraZenecaPhase 3 Active not recruiting732 enrolled 22 charts 1 FDA
NCT02246621 2026-02-03MONARCH 3Eli Lilly and CompanyPhase 3 Active not recruiting493 enrolled 23 charts 1 FDA
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA